Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way

Sep 29 2016

• By Sten Stovall

Cystic fibrosis word cloud

Related Content

Why Pricing <em>Orkambi</em> Below <em>Kalydeco</em> Is A Savvy Strategy For Vertex

Jul 13 2015

Vertex’s <em>Orkambi </em>Approved With Broad Label For Cystic Fibrosis

Jul 02 2015

Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Jan 31 2012

Vertex's VX-661 Has Positive Outlook Despite Futility Finding

Aug 16 2016

Related Companies

Vertex Pharmaceuticals Incorporated

PTC Therapeutics, Inc.

Roche Holding AG

Novartis AG

Chiesi Farmaceutici S.p.A.

Additional Topics

Market Intelligence Commercial Respiratory BioPharmaceutical

More from Respiratory

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window